Validea's guru fundamental report rates Johnson & Johnson (JNJ), a large-cap Biotechnology & Drugs stock, at 88% using Partha Mohanram's P/B Growth Investor model. This score indicates high interest, suggesting JNJ exhibits characteristics associated with sustained future growth for low book-to-market stocks, despite failing the Research and Development to Assets criterion. Mohanram's model is significant for its ability to identify outperforming growth stocks, challenging traditional academic perspectives.
Johnson & Johnson (JNJ) has received a highly favorable rating of 88% from Validea's P/B Growth Investor model, which is based on the academic strategy of Partha Mohanram. This score indicates significant interest from a model designed to identify low book-to-market stocks with characteristics of sustained future growth. As a large-cap stock in the Biotechnology & Drugs industry, JNJ's high score is supported by its successful performance across multiple fundamental criteria, including Return on Assets, Cash Flow from Operations to Assets, and stability in both ROA and sales variance. However, the analysis reveals a notable point of weakness, as the company failed the test for Research and Development to Assets. While the model's overall positive assessment suggests JNJ's operational and financial strengths currently outweigh this concern, the R&D metric's failure is a critical data point for a company operating in an innovation-driven sector.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.65
Ticker Sentiment
